Lactobacillus reuteri–induced Regulatory T cells Protect against an Allergic Airway Response in Mice
Top Cited Papers
- 1 February 2009
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 179 (3), 186-193
- https://doi.org/10.1164/rccm.200806-951oc
Abstract
We have previously demonstrated that oral treatment with live Lactobacillus reuteri can attenuate major characteristics of the asthmatic response in a mouse model of allergic airway inflammation. However, the mechanisms underlying these effects remain to be determined.We tested the hypothesis that regulatory T cells play a major role in mediating L. reuteri-induced attenuation of the allergic airway response.BALB/c mice were treated daily with L. reuteri by gavage. Flourescent-activated cell sorter analysis was used to determine CD4(+)CD25(+)Foxp3(+)T cell populations in spleens following treatment with L. reuteri or vehicle control. Cell proliferation assays were performed on immunomagnetic bead separated CD4(+)CD25(+) and CD4(+)CD25(-) T cells. CD4(+)CD25(+) T cells isolated from, ovalbumin naive, L. reuteri treated mice were transferred into ovalbumin-sensitized mice. Following antigen challenge the airway responsiveness, inflammatory cell influx and cytokine levels in bronchoalveolar lavage fluid of recipient mice were assessed.Following 9 days of oral L. reuteri treatment, the percentage and total number of CD4(+)CD25(+)Foxp3(+)T cells in spleens significantly increased. CD4(+)CD25(+) cells isolated from L. reuteri-fed animals also had greater capacity to suppress T-effector cell proliferation. Adoptive transfer of CD4(+)CD25(+) T cells from L. reuteri-treated mice to ovalbumin-sensitized animals attenuated airway hyper-responsiveness and inflammation in response to subsequent antigen challenge.These results strongly support a role for nonantigen-specific CD4(+)CD25(+)Foxp3(+) regulatory T cells in attenuating the allergic airway response following oral treatment with L. reuteri. This potent immuno-regulatory action may have therapeutic potential in controlling the Th2 bias observed in atopic individuals.This publication has 39 references indexed in Scilit:
- Commensal-Induced Regulatory T Cells Mediate Protection against Pathogen-Stimulated NF-κB ActivationPLoS Pathogens, 2008
- Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trialJournal of Allergy and Clinical Immunology, 2007
- Oral Treatment with Live Lactobacillus reuteri Inhibits the Allergic Airway Response in MiceAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Perinatal maternal application of Lactobacillus rhamnosus GG suppresses allergic airway inflammation in mouse offspringClinical & Experimental Allergy, 2007
- Probiotic‐induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory‐dependent mechanisms in a murine model of asthmaClinical & Experimental Allergy, 2006
- Effects of probiotics on atopic dermatitis: a randomised controlled trialArchives of Disease in Childhood, 2005
- Selective probiotic bacteria induce IL-10–producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell–specific intercellular adhesion molecule 3–grabbing nonintegrinJournal of Allergy and Clinical Immunology, 2005
- Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trialThe Lancet, 2003
- Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cellsNature Medicine, 2002
- Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trialThe Lancet, 2001